ESMO 2021: First-line nivolumab/ipilimumab – probability of survival in 5-year follow-up
The use of two medicines together (combination therapies) for previously [...]
ESMO 2021: Alternative treatment schedule for ipilimumab plus nivolumab in first-line treatment of advanced RCC (PRISM)
Ipilimumab plus nivolumab is a standard first-line treatment for patients [...]
ASCO 2021: Nivolumab plus ipilimumab for the treatment of kidney cancer brain metastases
Brain metastases resulting from the spread of renal cell carcinoma [...]
ASCO 2021: Baseline characteristics affect survival with nivolumab plus cabozantinib
Ongoing results from the phase 3 CheckMate-9ER clinical trial with [...]
ASCO 2021: Nivolumab plus cabozanitinib for non-clear cell kidney cancer
The cabozantinib/nivolumab combination has been shown to be effective at [...]
ASCO 2021: Cobozantinib plus nivolumab combination for non-clear cell kidney cancer
The cabozantinib/nivolumab combination has been shown to be effective at [...]
Nivolumab/cabozantinib combination approved in EU for first-line kidney cancer treatment
The European Commission has approved the use of the nivolumab [...]
Nivolumab/cabozantinib combination recommended for EMA approval for first-line kidney cancer
The Committee for Medicinal Products for Human Use (CHMP) of [...]
ASCO GU 2021: Long-term follow-up of kidney cancer patients on nivolumab plus ipilimumab combination
Long-term follow-up data from the CheckMate-214 study of the nivolumab [...]
ASCO GU 2021: Nivolumab plus ipilimumab combination in patients with non-clear cell kidney cancer
Data from the CheckMate-920 study on the safety and effectiveness [...]
